Efficacy and safety of etrolizumab in treatment of moderate to severe ulcerative colitis: A systematic review and meta-analysis.

Karam R MotaweaYomna A AbdelghafarYossef H AbdelQadirMerna M AboeleneinNancy IbrahimMohamed M BelalRowan H ElhalagLina T KhairyAgyad BakkourAli H H MuwailiFatima A A AbdelmajidMhd K AlbuniElias BattikhBisher SawafEman M S AhmedDhuha H H MuwailiSarya Swed

Published in: Health science reports (2024)

Our results show that etrolizumab is an effective and safe drug for the induction and maintenance of clinical remission in moderate to severe ulcerative colitis patients, as proved by histologic and endoscopic findings. Future randomized trials are still needed to compare etrolizumab to the other agents and further establish its value for the practice.

Keyphrases

ulcerative colitis
end stage renal disease
ejection fraction
early onset
newly diagnosed
chronic kidney disease
high intensity
primary care
healthcare
emergency department
prognostic factors
drug induced
current status
rheumatoid arthritis
patient reported outcomes
systemic lupus erythematosus
patient reported